7Greaves MW, Weinstein GD. Treatment of Psoriasis[J]. N Engl J Med, 1995, 332 (9) :581 -589.
8Griffiths CE. The immunological basis of psoriasis[J]. J Eur Acad Dermatol Venereol, 2003,17(Suppl 2) :1 -5.
9Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons leaned, unresolved issues and future directions[ J]. Curr Dir Autoimmun, 2010, 11 : 180 -210.
10Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TI-II ellector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients [ J ]. The Journal of investigative dermatology, 1999,113 ( 5 ) : 752 -759.
